Editorials

Treatment of brucellosis

BMJ 2008; 336 doi: http://dx.doi.org/10.1136/bmj.39497.431528.80 (Published 27 March 2008) Cite this as: BMJ 2008;336:678
  1. Georgios Pappas, head
  1. 1Institute of Continuing Medical Education of Ioannina, 45333, Ioannina, Greece
  1. gpele{at}otenet.gr

    Regimens containing aminoglycosides are most effective but difficult to implement in practice

    Although human brucellosis has been recognised for 121 years it remains difficult to treat.1 It is transmitted mainly from domestic animals to humans through direct contact, contaminated animal products (particularly dairy products), and by inhalation of infectious particles. Brucella has developed many ways to evade the human immune system, and it induces a disease that is often relapsing or chronic. The geographical distribution of the disease is constantly changing, with new foci emerging,2 and Brucellaalso has the potential to be used in biowarfare as it is easily produced in a steady aerosolised form.3 Brucella’s unique interaction with the human immune system means that a protracted therapeutic regimen with a combination of antibiotics is needed to avoid treatment failure and relapses, serious complications, or residual damage from focal disease.4 5 The optimal treatment regimen is debatable.

    In …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe